Hikma Pharmaceuticals


The ongoing transition story hits another roadblock

25/05/22 -"Considering the group was already facing multiple headwinds – deteriorating generics pricing environment in the US, market share losses for its recently launched products and product launch delays – ..."

Pages
48
Language
English
Published on
25/05/22
You may also be interested by these reports :
22/06/22
However, these expenses are investment into growth and should continue to support Astra’s sector-leading top-line growth in the coming years. ...

15/06/22
Roadshow highlights: CFO Suter shows himself very confident to reach Siegfried’s 2022E guidance and mid-term targets

03/06/22
Sentiment for the current business environment might be far better than expected by many market participants, but question mark on the development ...

02/06/22
We have revised downwards our profitability expectations due to the significant price increases for consumables and single-use products. Compounded ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO